Statement of Beneficial Ownership (sc 13d)
March 22 2017 - 3:36PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13D
Under
the Securities Exchange Act of 1934
Matinas Biopharma
Holdings, Inc.
(Name
of Issuer)
Common Stock,
par value $0.0001 per share
(Title
of Class of Securities)
576810105
(CUSIP
Number)
Jennifer
Lorenzo
c/o GJG Capital, LLC
107 Circle Road
Staten Island, NY 10304
(917) 439-3333
(Name,
Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
March 15, 2017
(Date
of Event which Requires Filing of this Statement)
If the filing
person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and
is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
o
Note
:
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7
for other parties to whom copies are to be sent.
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in
a prior cover page.
The information
required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
CUSIP No. 576810105
|
|
13D
|
|
Page 2 of 8 Pages
|
|
|
|
|
|
1.
|
|
NAMES OF REPORTING PERSONS
GJG Life Sciences, LLC
|
|
|
2.
|
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)
o
(b)
o
|
|
|
3.
|
|
SEC
USE ONLY
|
|
|
4.
|
|
SOURCE
OF FUNDS (see instructions)
OO
|
|
|
5.
|
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
o
|
|
|
6.
|
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Delaware
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
|
7.
|
|
SOLE
VOTING POWER
0
|
|
8.
|
|
SHARED
VOTING POWER
15,396,760*
|
|
9.
|
|
SOLE
DISPOSITIVE POWER
0
|
|
10.
|
|
SHARED
DISPOSITIVE POWER
15,396,760*
|
|
|
|
|
|
11.
|
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
15,396,760*
|
|
|
12.
|
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions)
o
|
|
|
13.
|
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
24.5%**
|
|
|
14.
|
|
TYPE
OF REPORTING PERSON (see instructions)
OO
|
|
|
* Includes
4,900,000 shares of Issuer common stock, par value $0.0001 per share (the “Common Stock”) issuable upon conversion
of Class A Convertible Preferred Stock of the Issuer (the “Class A Preferred Stock”).
** Percentage
of class calculated based on 58,048,412 total outstanding shares of Common Stock as of November 11, 2016, as reported in the Issuer’s
Form 10-Q, filed with the Securities and Exchange Commission (“SEC”) on November 14, 2016.
|
|
|
|
|
CUSIP No. 576810105
|
|
13D
|
|
Page 3 of 8 Pages
|
|
|
|
|
|
1.
|
|
NAMES OF REPORTING PERSONS
GJG Capital, LLC
|
|
|
2.
|
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)
o
(b)
o
|
|
|
3.
|
|
SEC
USE ONLY
|
|
|
4.
|
|
SOURCE
OF FUNDS (see instructions)
OO
|
|
|
5.
|
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
o
|
|
|
6.
|
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Delaware
|
|
|
|
|
|
|
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
|
|
7.
|
|
SOLE
VOTING POWER
0
|
|
8.
|
|
SHARED
VOTING POWER
15,396,760*
|
|
9.
|
|
SOLE
DISPOSITIVE POWER
0
|
|
10.
|
|
SHARED
DISPOSITIVE POWER
15,396,760*
|
|
|
|
|
|
11.
|
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
15,396,760*
|
|
|
12.
|
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions)
o
|
|
|
13.
|
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
24.5%**
|
|
|
14.
|
|
TYPE
OF REPORTING PERSON (see instructions)
OO
|
|
|
|
|
|
|
|
|
|
|
|
* Includes
4,900,000 shares of Issuer Common Stock issuable upon conversion of Class A Preferred Stock.
** Percentage
of class calculated based on 58,048,412 total outstanding shares of Common Stock as of November 11, 2016, as reported in the Issuer’s
Form 10-Q, filed with the SEC on November 14, 2016.
|
|
|
|
|
CUSIP No. 576810105
|
|
13D
|
|
Page 4 of 8 Pages
|
|
|
|
|
|
1.
|
|
NAMES OF REPORTING PERSONS
Jennifer Lorenzo
|
|
|
2.
|
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)
o
(b)
o
|
|
|
3.
|
|
SEC
USE ONLY
|
|
|
4.
|
|
SOURCE
OF FUNDS (see instructions)
PF
|
|
|
5.
|
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
o
|
|
|
6.
|
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Jennifer Lorenzo is a US Citizen
|
|
|
|
|
|
|
|
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
|
|
7.
|
|
SOLE
VOTING POWER
521,243
|
|
8.
|
|
SHARED
VOTING POWER
15,396,760*
|
|
9.
|
|
SOLE
DISPOSITIVE POWER
521,243
|
|
10.
|
|
SHARED
DISPOSITIVE POWER
15,396,760*
|
|
|
|
|
|
11.
|
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
15,918,003*
|
|
|
12.
|
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions)
o
|
|
|
13.
|
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
25.4%**
|
|
|
14.
|
|
TYPE
OF REPORTING PERSON (see instructions)
IN
|
|
|
|
|
|
|
|
|
|
|
|
* Includes
4,900,000 shares of Issuer Common Stock issuable upon conversion of Class A Preferred Stock.
** Percentage
of class calculated based on 58,048,412 total outstanding shares of Common Stock as of November 11, 2016, as reported in the Issuer’s
Form 10-Q, filed with the SEC on November 14, 2016.
|
|
|
|
|
CUSIP No. 576810105
|
|
13D
|
|
Page 5 of 8 Pages
|
|
|
|
|
|
Item 1. Security
and Issuer.
This
Schedule 13D relates to the common stock, par value $$0.0001 per share (the “Common Stock”), of Matinas Biopharma
Holdings, Inc., a Delaware corporation (the “Issuer”), whose principal executive officers are located at 1545 Route
206 South, Suite 302, Bedminster, NJ 07921.
Item 2. Identity
and Background.
|
(a)
|
This
Schedule 13D is filed by GJG Life Sciences, LLC, a Delaware limited liability company
(“GJG Life”), GJG Capital, LLC, a Delaware limited liability company (“GJG
Capital”) and the Managing Member of GJG Life and Jennifer Lorenzo, the sole Member
and Manager (the “Managing Member”) of GJG Capital. GJG Life, GJG Capital
and the Managing Member are referred to herein collectively as the “Reporting Persons”.
|
|
(b)
|
The
address of the Reporting Persons is c/o GJG Capital, LLC, 107 Circle Road, Staten Island,
NY 10304.
|
|
(c)
|
The
principal business of GJG Capital is serving as the Managing Member of GJG Life. The
principal business of the Managing Member is serving as the manager of GJG Capital. GJG
Life is a private investment vehicle whose principal business consists of acquiring shares
in public and private companies. Because of GJG Capital’s and the Managing Member’s
relationship to GJG Life, each of GJG Capital and the Managing Member may be deemed to
beneficially own the securities hold by GJG Life. GJG Capital and the Managing Member
each disclaim beneficial ownership of the securities held by GJG Life except to the extent
of their respective pecuniary interests therein.
|
|
(d)
|
–
(e) During the past five years, none of the Reporting Persons and, to the best of the
Reporting Persons’ knowledge, no other person identified in response to this Item
2 has been (i) convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors) or (ii) a party to any civil proceeding of a judicial or administrative
body of competent jurisdiction and as a result of such proceeding was or is subject to
a judgment, decree or final order enjoining future violations of, or prohibiting or mandating
activities subject to, federal or state securities laws, or finding any violation with
respect to such laws.
|
|
(f)
|
GJG
Life and GJG Capital are Delaware limited liability companies and the Managing Member
is a US Citizen.
|
Item 3. Source or Amount
of Funds or Other Consideration.
During the period
from August 2013 through April 2015, GJG Life acquired a total of 9,127,591 shares of Common Stock, warrants (the “Warrants”)
to acquire 1,369,169 shares of Common Stock at an exercise price of $0.75 per share, and 490,000 shares of Class A Convertible
Preferred Stock of the Issuer (the “Class A Preferred Stock”), convertible into 4,900,000 shares of Common Stock.
The acquisitions of the Common Stock, Warrants and Class A Preferred were funded by capital contributions of the Class B Members
of GJG Life. During the period from July 2013 to January 2017, the Managing Member acquired a total of 625,000 shares of Common
Stock. Such acquisitions were funded by the Managing Member’s personal funds. Subsequent thereto, during the
period from January to February 2017, the Managing Member sold 103,757 shares of Common Stock.
On
March 1, 2017, the Issuer filed a registration statement on Form 8A-12b (the “Registration Statement”) with the Securities
and Exchange Commission registering the Common Stock under Section 12(b) of the Exchange Act of 1934, as amended.
|
|
|
|
|
CUSIP No. 576810105
|
|
13D
|
|
Page 6 of 8 Pages
|
|
|
|
|
|
On March
15, 2017, GJG Life exercised the Warrants and acquired 1,369,169 shares of Common Stock at an exercise price of $0.75 per share.
Payment of the exercise price of the Warrants was funded by capital contributions of the Class B Members
of GJG Life.
Item 4. Purpose
of Transaction.
GJG Life
acquired the shares of Common Stock for investment in the ordinary course of business, as it believed that the shares of Common
Stock represented an attractive investment opportunity. As described in Item 3 above, GJG Life initially acquired the Issuer securities
prior to the Issuer filing its Registration Statement.
Other than described
above, none of the Reporting Persons has any plans or proposals of the type referred to in Items 4(a) through (j) of Schedule
13D. The Reporting Persons, however, each retain the right to change its plans at any time, as it deems appropriate, in light
of its ongoing evaluation of (i) its business and liquidity objectives; (ii) industry, economic or securities markets conditions;
(iii) alternative investment opportunities; and (iv) other relevant factors.
Item 5. Interest
in Securities of the Issuer.
|
(a)
|
Following
the exercise of the Warrant, GJG Life beneficially owns an aggregate of 10,496,760 shares
of Common Stock and 490,000 shares of Class A Preferred Stock. The Class A Preferred
Stock is convertible into 4,900,000 shares of Common Stock. The Issuer Common Stock owned
by GJG Life and the shares of Common Stock issuable upon conversion of the Class A Stock,
collectively represent 24.5% of the outstanding Common Stock of the Issuer (based on
58,048,412 total outstanding shares of Common Stock as of November 11, 2016, as reported
in the Issuer’s Form 10-Q, filed with the SEC on November 14, 2016). The Managing
Member owns 521,243 shares of Common Stock of the Issuer, representing 0.9% of the outstanding
Common Stock of the Issuer (based on 58,048,412 total outstanding shares of Common Stock
as of November 11, 2016, as reported in the Issuer’s Form 10-Q, filed with the
SEC on November 14, 2016). GJG Capital in the Managing Member of GJG Life and the Managing
Member is the sole member and manager of GJG Capital. Because of GJG Capital’s
and the Managing Member’s relationship to GJG Life, each of GJG Capital and the
Managing Member may be deemed to beneficially own the securities hold by GJG Life. GJG
Capital and the Managing Member each disclaim beneficial ownership of the securities
held by GJG Life except to the extent of their respective pecuniary interests therein.
|
|
(b)
|
GJG
Life, GJG Capital and the Managing Member have shared voting and dispositive power over
10,496,760 shares of Common Stock of the Issuer and 4,900,000 shares of Class A Convertible
Preferred Stock of the Issuer. In addition, the Managing Member has sole voting and dispositive
power over the 521,243 shares of Common Stock of the Issuer owned by the Managing Member.
|
|
(c)
|
Except
as otherwise described in this Schedule 13D, the Reporting Persons have not effected
any transactions in the common stock or other equity security of the Issuer during the
last 60 days.
|
|
(d)
|
Except
as otherwise described in this Schedule 13D, no person other than the Reporting Persons
are known to have the right to receive, or the power to direct the receipt of dividends
from, or proceeds from the sale of, the beneficially owned common stock.
|
|
|
|
|
|
CUSIP No. 576810105
|
|
13D
|
|
Page 7 of 8 Pages
|
Item 6. Contracts,
Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
Except as
set forth in this Schedule 13D, to the best knowledge of the Reporting Persons, there are no other contracts, arrangements, understandings
or relationships (legal or otherwise) between the persons named in Item 2 and any person with respect to any securities of the
Issuer, including but not limited to: transfer or voting of any of the securities of the Issuer or of its subsidiaries, joint
ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding
of proxies or a pledge or contingency the occurrence of which would give another person voting power over the securities of the
Issuer.
Item 7. Material
to Be Filed as Exhibits.
Exhibit A: Joint filing
Agreement.
|
|
|
|
|
CUSIP No. 576810105
|
|
13D
|
|
Page 8 of 8 Pages
|
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated:
March 22, 2017
|
|
|
|
GJG Life
Sciences, LLC
|
|
|
|
|
By:
|
/s/
GJG Capital, LLC
|
|
|
GJG Capital, LLC
|
|
|
Managing
Member
|
|
|
By:
/s/ Jennifer Lorenzo, Managing Member
|
|
|
|
|
GJG Capital,
LLC
|
|
|
|
|
By:
|
/s/
Jennifer Lorenzo
|
|
|
Jennifer Lorenzo
|
|
|
Managing
Member
|
|
|
|
/s/
Jennifer Lorenzo
|
|
Jennifer Lorenzo
|
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Apr 2024 to May 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From May 2023 to May 2024